• CENPO Super-Enhancer Drives Prognosis and Therapy Resistance

  2026-05-19

  The referenced study establishes CENPO as an oncogenic super-enhancer in lung adenocarcinoma (LUAD), revealing its direct association with poor prognosis, immune modulation, and drug resistance. Through integrated bioinformatics and experimental validation, the authors identify CENPO as a prognostic marker and therapeutic target, with implications for FGFR pathway inhibition strategies.

• I-BET151 (GSK1210151A): Technical Guide for BET Inhibition A

  2026-05-19

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed for precise modulation of BRD2, BRD3, and BRD4 in cancer biology workflows. This compound addresses the need for reproducible, targeted epigenetic modulation in apoptosis and cell cycle arrest assays but is not suitable for diagnostic or therapeutic use. Researchers should carefully follow solubility and storage guidelines to ensure reliable results.

• Vincristine Sulfate in Cancer Research: Protocols & Solution

  2026-05-18

  Vincristine sulfate is a reference-standard antitumor agent trusted for its precision in disrupting microtubule dynamics and driving reproducible results in cancer research. This article delivers actionable protocols, troubleshooting strategies, and advanced workflow enhancements, enabling scientists to fully leverage APExBIO's validated Vincristine sulfate (SKU A1765) for both in vitro and in vivo oncology applications.

• Propranolol in Emotional Memory Research: Mechanisms and Pro

  2026-05-18

  Explore how Propranolol, a non-selective β-adrenergic receptor blocker, enables advanced emotional memory modulation research. This article delivers a rigorous analysis of mechanisms, protocol optimization, and translational insights, distinguishing itself from workflow-focused guides.

• Hesperadin: Precision Aurora B Kinase Inhibitor for Mitotic

  2026-05-17

  Hesperadin enables researchers to dissect mitotic progression and spindle assembly checkpoint regulation with exceptional specificity. Its robust inhibition of Aurora B kinase unlocks advanced applications for cancer research and cell cycle analysis, with well-defined phenotypic and molecular readouts.

• Tariquidar (XR9576): Precision Inhibition in Drug Resistance

  2026-05-16

  Tariquidar (XR9576) is revolutionizing drug resistance research by enabling robust, selective inhibition of P-glycoprotein in high-viscosity tumor models. Its unique properties make it essential for dissecting transporter-mediated drug disposition, even under challenging chemoresistance conditions.

• Cyclic di-GMP: Applied Workflows for Biofilm and Immune Rese

  2026-05-15

  Cyclic di-GMP serves as a linchpin for both bacterial biofilm regulation and mammalian immune modulation workflows. This guide translates the latest mechanistic insights and practical troubleshooting tips into actionable steps for researchers aiming to leverage APExBIO's high-purity cyclic di-GMP across microbiology and immunotherapy studies.

• Minoxidil Sulphate: Next-Gen Strategies in Vascular Research

  2026-05-15

  This thought-leadership article explores how Minoxidil sulphate (2-amino-6-imino-4-(piperidin-1-yl)pyrimidin-1(6H)-yl hydrogen sulfate) is reshaping translational research in vascular biology and hair growth. By weaving mechanistic insight with actionable guidance, we examine evidence for potassium channel modulation, highlight new experimental frontiers, and provide grounded recommendations for researchers aiming to elevate the rigor and impact of their work.

• Phenytoin in Myelin Remodeling: Bridging Mechanism and Trans

  2026-05-14

  This thought-leadership article explores how Phenytoin (5,5-diphenylimidazolidine-2,4-dione) enables new frontiers in sodium channel modulation research by bridging mechanistic insight, protocol optimization, and translational strategy in CNS demyelination models. Anchored by the latest evidence on dynamic myelin remodeling, we illuminate best practices for electrophysiology and disease modeling, contextualize competitive products, and articulate the unique value of APExBIO’s high-purity Phenytoin for researchers seeking reproducible, impactful data.

• Urolithin A: Advancing Mitochondrial Quality Control in Agin

  2026-05-14

  Discover how Urolithin A, a microbiota-derived metabolite, uniquely advances mitochondrial biogenesis research and cellular metabolism. This article delivers scientific depth on its mechanisms, differentiating it from standard mitophagy activators.

• YBX1-Linked SHANK3 Methylation and Expression in Schizophren

  2026-05-13

  This study reveals how hypermethylation of the SHANK3 promoter, mediated by YBX1, alters SHANK3 expression in cortical interneurons derived from iPSCs in schizophrenia. The findings highlight a peripheral biomarker potential for SHANK3 methylation and expand our understanding of epigenetic regulation in neurodevelopmental disorders.

• Caffeine (1,3,7-trimethylpurine-2,6-dione): Applied Lab Work

  2026-05-13

  Caffeine stands out in experimental protocols for its dual role as an adenosine receptor antagonist and a modulator of energy metabolism, enabling targeted studies in cancer and metabolic research. This guide details best practices and troubleshooting strategies, leveraging recent advances and APExBIO’s high-purity reagent standards for reproducible results.

• Cyclic di-GMP: Key Intracellular Second Messenger in Biofilm

  2026-05-12

  Cyclic di-GMP is a central intracellular second messenger that regulates bacterial biofilm formation and genome stability. Recent research confirms its antitoxin role in modulating antibiotic persistence, while its capacity as a STING agonist enables advanced immune modulation research. This article delivers atomic, citation-backed facts for evidence-based workflows in infection biology and cancer immunotherapy studies.

• Staurosporine: Precision Kinase Inhibition for Next-Gen Cell

  2026-05-12

  Explore how Staurosporine, a broad-spectrum serine/threonine protein kinase inhibitor, enables advanced apoptosis induction and kinase pathway profiling in modern disease models. This article uniquely bridges cryopreservation breakthroughs and practical assay optimization for cancer research.

• Spleen-Targeted Neoantigen mRNA Vaccine Induces TLS in HCC

  2026-05-11

  Lin et al. present a spleen-targeted neoantigen mRNA vaccine (STNvac) that elicits potent antitumor immunity in hepatocellular carcinoma by mobilizing ISG15+ CD8+ T cells and inducing tertiary lymphoid structure (TLS) formation. This work advances understanding of organ-targeted mRNA immunotherapy and provides a mechanistic rationale for improving mRNA vaccine efficacy in immune-refractory tumors.

613 records 8/41 page Previous Next First page 上5页 678910 下5页 Last page